National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN ORP Grant History
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Learn more about clinical trials at this NCCN Member Institution.

Profile

One of the nation's leading cancer research and treatment centers, the UAB Comprehensive Cancer Center is the only NCI-designated comprehensive cancer center located in a six-state area that includes Alabama, Mississippi, Louisiana, Arkansas, South Carolina, and Georgia. UAB’s cancer services are routinely recognized as among the top cancer programs in the nation by U.S. News & World Report.

From bench to bedside, the UAB Comprehensive Cancer Center is at the forefront of improving cancer prevention, diagnosis, and treatment, and researchers here have pioneered advances in chemotherapy, surgery, radiotherapy, immunotherapy, and nutrition.

The UAB Comprehensive Cancer Center is recognized around the world as a leader in developing innovative monoclonal antibody approaches to cancer therapy. The Center conducts clinical trials using genetically engineered monoclonal antibodies alone or armed with a payload of immunotoxins, chemotherapy drugs, or radioactive isotopes to specifically target a broad array of cancers, including breast, gastrointestinal tract, lung, ovary, head and neck, brain tumors, and lymphomas.

The renowned Cancer Vaccine Development team at the UAB Comprehensive Cancer Center is charged by the NCI with developing a series of cancer vaccine trials using genetically engineered vaccine reagents. The Center has developed four therapeutic vaccine strategies:

o A naked DNA gene therapy vaccine for colon cancer

o An antitumor vaccine for patients with hormone-responsive metastatic breast cancer

o Genetically engineered vaccinia virus (smallpox) to eradicate colon cancer

o Studies to test immunization to the CEA antigen for several different cancer sites including colon and breast. As an overall vaccine strategy, the Cancer Center is exploring a broad array of approaches to induce immune response to molecules prevalent in tumor cells.

The UAB Comprehensive Cancer Center offers a full array of treatment options from interdisciplinary clinics to the latest techniques in bone marrow transplantation. It has an outstanding faculty of 300 physicians and researchers, many of whom are internationally and nationally recognized for their expertise in oncology. The UAB program in Supportive and Palliative Medicine is among the foremost in the nation. The Center treats an estimated 4,000 new patients each year.